

Ha

Kn

Li

SF

SS

SH

Wa

Wi

WL



**PAN MERSEY AREA PRESCRIBING COMMITTEE**  
**PRESCRIBING POLICY STATEMENT**  
**APC BOARD DATE: 26 SEP 2018**



**Pan Mersey**  
Area Prescribing Committee

## **DUPIBUMAB solution for injection (Dupixent® ▼) for atopic dermatitis**

**RED**

**The Pan Mersey Area Prescribing Committee recommends the prescribing of Dupilumab solution for injection (Dupixent® ▼), by specialists only, for the treatment of moderate to severe atopic dermatitis in adults in accordance with NICE TA534.**

NICE technology appraisal (TA) 534<sup>1</sup> [01 August 2018] recommends dupilumab as an option for treating moderate to severe atopic dermatitis in adults, only if:

- > the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated
- > the company provides dupilumab according to the commercial arrangement.

Stop dupilumab at 16 weeks if the atopic dermatitis has not responded adequately. An adequate response is:

- > at least a 50% reduction in the Eczema Area and Severity Index score (EASI 50) from when treatment started and
- > at least a 4-point reduction in the Dermatology Life Quality Index (DLQI) from when treatment started.

Prescribing and monitoring of therapy must be retained by a specialist in the management of moderate to severe atopic dermatitis.

NICE estimates the cost of implementing this TA as £5,933 per 100,000 population in 2018/19, rising to £59,248 per 100,000 population by 2022/23 once the PAS discount is applied. This is in addition to existing costs for ongoing topical corticosteroid treatment. Costings assume that oral DMDs have been discontinued.

These recommendations are not intended to affect treatment with dupilumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

### **Reference:**

1. National Institute for Health and Care Excellence. Technology Appraisal Guidance (TA) 534: Dupilumab for treating moderate to severe atopic dermatitis, 1<sup>st</sup> August 2018. Accessed 17.8.18 at <https://www.nice.org.uk/guidance/ta534>

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.